Yes, an orphan drug (for a rare disease) can absolutely receive accelerated approval from the FDA, as these expedited pathways often work together to get treatments to rare disease patients faster, leveraging the Orphan Drug Act's incentives with the Accelerated Approval's ability to use surrogate endpoints for serious conditions with unmet needs.
Many orphan drugs, especially for rare cancers, utilize this combination, getting earlier access through faster reviews and smaller trials.
How They Work Together:
Orphan Drug Designation: This status, given to drugs for rare diseases (affecting <200,000 people in the U.S.), provides financial incentives, tax credits, and market exclusivity, encouraging development.
Accelerated Approval: Allows the FDA to approve drugs for serious conditions based on a surrogate endpoint (like a biomarker) that predicts clinical benefit, rather than waiting for long-term outcomes.
Combined Benefits: An orphan drug targeting a rare, serious condition can get both designations, potentially receiving priority review (6-month review goal) and using surrogate endpoints, leading to much quicker patient access.
____
Per Mr. Hoffman comment Cytodyn is seeking Orphan Drug Approval.
Accelerated Approval can also have a rolling BLA review attached to it's Confirmary Trial period. Leading to full, unrestricted approval.
___
Sponsor(s) + Orphan Drug + AA = access to all applicable 7-10k diseases.
Supporting programs & incentives of Rare Diseases.
The Briefing Book meeting could absolutely include Dr. J & team requesting & receiving the guidance for it to all come together.
___
I'll take the obvious bet ---- Max Lataillade
Many orphan drugs, especially for rare cancers, utilize this combination, getting earlier access through faster reviews and smaller trials.
How They Work Together:
Orphan Drug Designation: This status, given to drugs for rare diseases (affecting <200,000 people in the U.S.), provides financial incentives, tax credits, and market exclusivity, encouraging development.
Accelerated Approval: Allows the FDA to approve drugs for serious conditions based on a surrogate endpoint (like a biomarker) that predicts clinical benefit, rather than waiting for long-term outcomes.
Combined Benefits: An orphan drug targeting a rare, serious condition can get both designations, potentially receiving priority review (6-month review goal) and using surrogate endpoints, leading to much quicker patient access.
____
Per Mr. Hoffman comment Cytodyn is seeking Orphan Drug Approval.
Accelerated Approval can also have a rolling BLA review attached to it's Confirmary Trial period. Leading to full, unrestricted approval.
___
Sponsor(s) + Orphan Drug + AA = access to all applicable 7-10k diseases.
Supporting programs & incentives of Rare Diseases.
The Briefing Book meeting could absolutely include Dr. J & team requesting & receiving the guidance for it to all come together.
___
I'll take the obvious bet ---- Max Lataillade
6
